Nishida Y, Kohno K, Kawamata T, Morimitsu K, Kuwano M, Miyakawa I
Department of Biochemistry, Oita Medical University, Japan.
Gynecol Oncol. 1995 Mar;56(3):357-61. doi: 10.1006/gyno.1995.1063.
Our purpose was to determine the correlation between cathepsin L mRNA levels and serum cathepsin L levels of patients with ovarian cancer. Moreover, we compared serum cathepsin L levels with cancer antigen 125 (CA125) and cancer antigen 72-4 (CA72-4) levels. Using an ELISA assay, serum samples of 30 patients with gynecological tumors were analyzed for cathepsin L, CA125, and CA72-4. We also examined whether cathepsin L gene expression was enhanced in ovarian cancer samples, by quantitative Northern blot analysis with a human cathepsin L complementary DNA (cDNA) probe. Significantly increased serum levels of cathepsin L in patients with ovarian cancer (P < 0.05) were observed. We also measured serum levels of CA125 and CA72-4 in the same patients. Compared with CA125 and CA72-4, cathepsin L showed a lower false-positive rate (27.2%) in gynecological diseases, and no correlation was observed between cathepsin L and CA125 or CA72-4 values. Moreover, ovarian cancer samples were found to express higher levels of cathepsin L mRNA than those of uterine cancer, benign ovarian tumor, and normal ovary samples. Our data demonstrated that serum cathepsin L may be useful in the early detection of ovarian cancer. Furthermore, the combination assay consisting of cathepsin L, CA125, and CA72-4 may be a more useful method than those currently in use for the detection of ovarian cancer.
我们的目的是确定卵巢癌患者组织蛋白酶L mRNA水平与血清组织蛋白酶L水平之间的相关性。此外，我们还比较了血清组织蛋白酶L水平与癌抗原125（CA125）和癌抗原72-4（CA72-4）水平。采用酶联免疫吸附测定法（ELISA），对30例妇科肿瘤患者的血清样本进行组织蛋白酶L、CA125和CA72-4分析。我们还通过用人组织蛋白酶L互补DNA（cDNA）探针进行定量Northern印迹分析，检测卵巢癌样本中组织蛋白酶L基因表达是否增强。结果观察到卵巢癌患者血清组织蛋白酶L水平显著升高（P < 0.05）。我们还测定了同一批患者的血清CA125和CA72-4水平。与CA125和CA72-4相比，组织蛋白酶L在妇科疾病中的假阳性率较低（27.2%），且组织蛋白酶L与CA125或CA72-4值之间未观察到相关性。此外，发现卵巢癌样本中组织蛋白酶L mRNA表达水平高于子宫癌、卵巢良性肿瘤和正常卵巢样本。我们的数据表明，血清组织蛋白酶L可能有助于卵巢癌的早期检测。此外，由组织蛋白酶L、CA125和CA72-4组成的联合检测方法可能比目前用于检测卵巢癌的方法更有用。
